KPMG has released its annual actuarial valuation of the asbestos-related disease liabilities associated with former James Hardie entities, assessed as at 31 March 2026. The valuation is conducted under the terms of the Amended Final Funding Agreement signed in November 2006, which established the Asbestos Injuries Compensation Fund (AICF) Trust to manage compensation claims arising from asbestos exposure linked to the company’s historical operations. The agreement represents a long-standing settlement framework between James Hardie Industries, the State of New South Wales, and affected parties.
The annual valuation process is a critical requirement of James Hardie’s historical settlement obligations. These actuarial assessments determine the estimated costs of future asbestos-related disease claims and compensation payments that must be funded through the AICF Trust. For investors, the valuation carries significant implications as changes in estimated liabilities can affect James Hardie’s balance sheet, cash flow obligations, and overall financial position. The company remains responsible for ensuring adequate funding for these obligations under the settlement agreement, making these annual assessments a key measure of contingent liability management.
The KPMG report incorporates claims data and information available as at 31 March 2026, reflecting the most recent trends in claim volumes, claim costs, and medical assessments. The actuarial team at KPMG comprises experienced actuaries with relevant professional qualifications including Fellowship of the Institute of Actuaries of Australia. The valuation has been prepared in accordance with established actuarial standards and the specific requirements of the Funding Agreement. These annual assessments are essential for maintaining transparency around the financial magnitude of asbestos-related liabilities and ensuring appropriate reserves are held.
The valuation is particularly significant given the long-tail nature of asbestos-related diseases. Many claims emerge years or decades after initial exposure, requiring sophisticated actuarial modeling to project future claim patterns. Changes in medical protocols, disease recognition, claim settlement patterns, mortality assumptions, and inflation rates can all materially influence the valuation outcome. The March 2026 assessment reflects current epidemiological data and historical claims experience through the first quarter of the financial year.
Investors should monitor how this valuation compares to previous years’ assessments and the company’s actual funding contributions. Material changes in the estimated liability could signal shifts in claim trends or medical outcomes related to asbestos exposure. The report will likely inform James Hardie’s financial statements for the year ending 30 June 2026 and any updates to management’s guidance regarding long-term funding requirements. The announcement has been flagged as price sensitive and material by the ASX.
View the full ASX announcement (PDF)
About James Hardie Industries plc (ASX: JHX)
James Hardie is the world’s leading manufacturer of fiber cement building products, offering solutions under brands including Hardie, fermacell, and AESTUVER. The company manufactures and supplies fiber cement, fiber gypsum, and cement bonded boards primarily to the construction and building markets. It operates across North America, Asia Pacific, and Europe, with significant presence in the United States, Australia, New Zealand, and European markets.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
